Table 2 Tumor response

From: Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial

  

m-FOLFOXIRI + cetuximab (n = 159)

m-FOLFOXIRI + bevacizumab (n = 162)

Median DpR (range)

 

57.3% (−42.6–100)

46.0% (−0.6–100)

Mean (95% CI)

 

55.2% (51.1–59.3)

47.3% (44.1–50.5)

Standard deviation (95% CI)

 

26.17 (23.6–29.4)

20.53 (18.5–23.0)

Welch’s t-test

 

p = 0.0029

 

Best response

Complete response

8 (5.0%)

3 (1.9%)

Partial response

105 (66.0%)

109 (67.3%)

Stable disease

44 (27.7%)

49 (30.2%)

Progressive disease

2 (1.3%)

0 (0%)

Not evaluated

0 (0%)

1 (0.6%)

Objective response rate (95% CI)

 

71.1% (64.0–78.1)

69.1% (62.0–76.2)

Chi-squared test

 

p = 0.71

 

Disease control rate (95% CI)

 

98.7% (97.0–100)

99.4% (98.2–100)

Chi-squared test

 

p = 0.55

 

R0 resection rate (95% CI)

 

26.4% (19.6–33.3)

21.0% (14.7–27.3)

Chi-squared test

 

p = 0.25

 
  1. Chi-squared test was used for the statistical analysis.
  2. CI confidence interval, DpR depth of response, m-FOLFOXIRI modified 5-FU, leucovorin, oxaliplatin and irinotecan.
Back to article page